Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BPTF | Q12830 | 1/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.47 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.47 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29723778 | 0.88 | SIRT6 (0.58) | BPTFADRB1SIRT6POLBMEN1 | |
| SCHEMBL10036164 | 0.88 | SIRT6 (0.58) | BPTFADRB1SIRT6POLBMEN1 | |
| SCHEMBL29045756 | 0.88 | SIRT6 (0.58) | BPTFADRB1SIRT6POLBMEN1 | |
| Hydrochloric Acid SCHEMBL30354933 | 0.86 | SIRT6 (0.57) | BPTFCHRNA7ADRB1SIRT6CHRNB2 | |
| Trifluoroacetic Acid SCHEMBL29580373 | 0.82 | CHRNB4 (0.46) | ADRB1SIRT6KCNJ1POLBKDM1A | |
| Trifluoroacetic Acid SCHEMBL3552142 | 0.76 | MAPT (0.49) | KCNJ1POLBMEN1KMT2AMAPT | |
| Trifluoroacetic Acid SCHEMBL3555102 | 0.76 | MAPT (0.49) | KCNJ1POLBMEN1KMT2AMAPT | |
| SCHEMBL14060301 | 0.75 | AKR1C3 (0.49) | ADRB1SIRT6POLBMEN1KMT2A | |
| SCHEMBL12939934 | 0.74 | MAPT (0.58) | ADRB1SIRT6POLBMEN1KMT2A | |
| SCHEMBL25191133 | 0.73 | POLB (0.54) | ADRB1SIRT6POLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3728234-B1 | RADIOLABELED COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2025-05-14 | — | — | EP | disclosed |
| US-11541132-B2 | Radiolabeled compounds | HOFFMANN-LA ROCHE INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20200316232-A1 | RADIOLABELED COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2020-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11541132-B2 | Radiolabeled compounds | SNCA, APP, BACE1 | BPTF 4147/4885CHRNA7 330/4885ADRB1 30/4885 |
| US-20200316232-A1 | RADIOLABELED COMPOUNDS | SNCA, APP, BACE1 | BPTF 4206/4885CHRNA7 358/4885ADRB1 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.